JOHNSON & JOHNSON (1JNJ.MI) Stock Fundamental Analysis

Europe • Euronext Milan • BIT:1JNJ • US4781601046

202.05 EUR
+3.29 (+1.66%)
Last: Feb 5, 2026, 07:00 PM
Fundamental Rating

5

Overall 1JNJ gets a fundamental rating of 5 out of 10. We evaluated 1JNJ against 55 industry peers in the Pharmaceuticals industry. 1JNJ has an average financial health and profitability rating. 1JNJ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • 1JNJ had positive earnings in the past year.
  • In the past year 1JNJ had a positive cash flow from operations.
  • In the past 5 years 1JNJ has always been profitable.
  • 1JNJ had a positive operating cash flow in 4 of the past 5 years.
1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCF1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • 1JNJ has a better Return On Assets (13.03%) than 80.00% of its industry peers.
  • With a decent Return On Equity value of 31.69%, 1JNJ is doing good in the industry, outperforming 72.73% of the companies in the same industry.
  • The Return On Invested Capital of 1JNJ (14.16%) is better than 70.91% of its industry peers.
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROIC 14.16%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1JNJ.MI Yearly ROA, ROE, ROIC1JNJ.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • With an excellent Profit Margin value of 27.26%, 1JNJ belongs to the best of the industry, outperforming 85.45% of the companies in the same industry.
  • In the last couple of years the Profit Margin of 1JNJ has grown nicely.
  • The Operating Margin of 1JNJ (27.00%) is better than 70.91% of its industry peers.
  • 1JNJ's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 68.14%, 1JNJ is in line with its industry, outperforming 41.82% of the companies in the same industry.
  • 1JNJ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27%
PM (TTM) 27.26%
GM 68.14%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
1JNJ.MI Yearly Profit, Operating, Gross Margins1JNJ.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1JNJ is still creating some value.
  • 1JNJ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
1JNJ.MI Yearly Shares Outstanding1JNJ.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
1JNJ.MI Yearly Total Debt VS Total Assets1JNJ.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 5.18 indicates that 1JNJ is not in any danger for bankruptcy at the moment.
  • 1JNJ has a Altman-Z score of 5.18. This is in the better half of the industry: 1JNJ outperforms 70.91% of its industry peers.
  • The Debt to FCF ratio of 1JNJ is 2.34, which is a good value as it means it would take 1JNJ, 2.34 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.34, 1JNJ belongs to the top of the industry, outperforming 83.64% of the companies in the same industry.
  • 1JNJ has a Debt/Equity ratio of 0.55. This is a neutral value indicating 1JNJ is somewhat dependend on debt financing.
  • 1JNJ has a Debt to Equity ratio (0.55) which is comparable to the rest of the industry.
  • Although 1JNJ does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Altman-Z 5.18
ROIC/WACC1.44
WACC9.86%
1JNJ.MI Yearly LT Debt VS Equity VS FCF1JNJ.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 1.07 indicates that 1JNJ should not have too much problems paying its short term obligations.
  • 1JNJ has a worse Current ratio (1.07) than 69.09% of its industry peers.
  • A Quick Ratio of 0.80 indicates that 1JNJ may have some problems paying its short term obligations.
  • 1JNJ has a Quick ratio of 0.80. This is in the lower half of the industry: 1JNJ underperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.8
1JNJ.MI Yearly Current Assets VS Current Liabilites1JNJ.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • 1JNJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.11%, which is quite good.
  • Measured over the past 5 years, 1JNJ shows a small growth in Earnings Per Share. The EPS has been growing by 6.11% on average per year.
  • The Revenue has been growing slightly by 6.05% in the past year.
  • The Revenue has been growing slightly by 2.67% on average over the past years.
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%

3.2 Future

  • 1JNJ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.17% yearly.
  • The Revenue is expected to grow by 5.37% on average over the next years.
EPS Next Y7.03%
EPS Next 2Y7.63%
EPS Next 3Y7.31%
EPS Next 5Y8.17%
Revenue Next Year6.76%
Revenue Next 2Y6.06%
Revenue Next 3Y6.02%
Revenue Next 5Y5.37%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
1JNJ.MI Yearly Revenue VS Estimates1JNJ.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
1JNJ.MI Yearly EPS VS Estimates1JNJ.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.08, 1JNJ is valued on the expensive side.
  • 1JNJ's Price/Earnings is on the same level as the industry average.
  • The average S&P500 Price/Earnings ratio is at 27.67. 1JNJ is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 20.62, 1JNJ is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of 1JNJ is on the same level as its industry peers.
  • 1JNJ is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 27.20, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.08
Fwd PE 20.62
1JNJ.MI Price Earnings VS Forward Price Earnings1JNJ.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as 1JNJ.
  • 1JNJ's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 29.31
EV/EBITDA 18.19
1JNJ.MI Per share data1JNJ.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of 1JNJ may justify a higher PE ratio.
PEG (NY)3.14
PEG (5Y)3.62
EPS Next 2Y7.63%
EPS Next 3Y7.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • 1JNJ has a Yearly Dividend Yield of 2.29%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 1.95, 1JNJ pays a bit more dividend than its industry peers.
  • 1JNJ's Dividend Yield is a higher than the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 2.29%

5.2 History

  • On average, the dividend of 1JNJ grows each year by 9.24%, which is quite nice.
Dividend Growth(5Y)9.24%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 1JNJ pays out 48.70% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of 1JNJ is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP48.7%
EPS Next 2Y7.63%
EPS Next 3Y7.31%
1JNJ.MI Yearly Income VS Free CF VS Dividend1JNJ.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
1JNJ.MI Dividend Payout.1JNJ.MI Dividend Payout, showing the Payout Ratio.1JNJ.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

JOHNSON & JOHNSON

BIT:1JNJ (2/5/2026, 7:00:00 PM)

202.05

+3.29 (+1.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)04-14
Inst Owners75.09%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap486.80B
Revenue(TTM)94.19B
Net Income(TTM)25.12B
Analysts75
Price Target181.8 (-10.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.29%
Yearly Dividend4.12
Dividend Growth(5Y)9.24%
DP48.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.42%
Min EPS beat(2)0.55%
Max EPS beat(2)2.3%
EPS beat(4)4
Avg EPS beat(4)2.37%
Min EPS beat(4)0.55%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.79%
EPS beat(12)11
Avg EPS beat(12)3.6%
EPS beat(16)14
Avg EPS beat(16)3.08%
Revenue beat(2)2
Avg Revenue beat(2)1.48%
Min Revenue beat(2)0.03%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.55%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.34%
Revenue beat(12)7
Avg Revenue beat(12)-2.01%
Revenue beat(16)7
Avg Revenue beat(16)-8.34%
PT rev (1m)-1.02%
PT rev (3m)15.82%
EPS NQ rev (1m)-3.57%
EPS NQ rev (3m)-3.57%
EPS NY rev (1m)-0.84%
EPS NY rev (3m)-0.83%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)0.06%
Revenue NY rev (1m)1.37%
Revenue NY rev (3m)1.37%
Valuation
Industry RankSector Rank
PE 22.08
Fwd PE 20.62
P/S 6.23
P/FCF 29.31
P/OCF 23.73
P/B 7.24
P/tB N/A
EV/EBITDA 18.19
EPS(TTM)9.15
EY4.53%
EPS(NY)9.8
Fwd EY4.85%
FCF(TTM)6.89
FCFY3.41%
OCF(TTM)8.52
OCFY4.21%
SpS32.42
BVpS27.89
TBVpS-6.16
PEG (NY)3.14
PEG (5Y)3.62
Graham Number75.78
Profitability
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROCE 17.53%
ROIC 14.16%
ROICexc 16.21%
ROICexgc 66.83%
OM 27%
PM (TTM) 27.26%
GM 68.14%
FCFM 21.27%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Debt/EBITDA 1.36
Cap/Depr 62.36%
Cap/Sales 5%
Interest Coverage 250
Cash Conversion 75.02%
Profit Quality 78.02%
Current Ratio 1.07
Quick Ratio 0.8
Altman-Z 5.18
F-Score4
WACC9.86%
ROIC/WACC1.44
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
EPS Next Y7.03%
EPS Next 2Y7.63%
EPS Next 3Y7.31%
EPS Next 5Y8.17%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
Revenue Next Year6.76%
Revenue Next 2Y6.06%
Revenue Next 3Y6.02%
Revenue Next 5Y5.37%
EBIT growth 1Y2.89%
EBIT growth 3Y12.1%
EBIT growth 5Y9.84%
EBIT Next Year23.35%
EBIT Next 3Y11.24%
EBIT Next 5Y7.6%
FCF growth 1Y-5.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.75%
OCF growth 3YN/A
OCF growth 5YN/A

JOHNSON & JOHNSON / 1JNJ.MI FAQ

What is the fundamental rating for 1JNJ stock?

ChartMill assigns a fundamental rating of 5 / 10 to 1JNJ.MI.


What is the valuation status of JOHNSON & JOHNSON (1JNJ.MI) stock?

ChartMill assigns a valuation rating of 3 / 10 to JOHNSON & JOHNSON (1JNJ.MI). This can be considered as Overvalued.


Can you provide the profitability details for JOHNSON & JOHNSON?

JOHNSON & JOHNSON (1JNJ.MI) has a profitability rating of 6 / 10.


What is the valuation of JOHNSON & JOHNSON based on its PE and PB ratios?

The Price/Earnings (PE) ratio for JOHNSON & JOHNSON (1JNJ.MI) is 22.08 and the Price/Book (PB) ratio is 7.24.


What is the financial health of JOHNSON & JOHNSON (1JNJ.MI) stock?

The financial health rating of JOHNSON & JOHNSON (1JNJ.MI) is 5 / 10.